teriflunomide / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 14 Diseases   33 Trials   33 Trials   2608 News 


«12...1516171819202122232425...3132»
  • ||||||||||  glatiramer acetate / Generic mfg.
    Clinical, Observational data, Journal:  The presence of SARS-CoV2 antibodies in MS patients. (Pubmed Central) -  May 15, 2021   
    The low incidence of SARS CoV2 antibodies following infection suggests that certain DMTs may alter SARS CoV2-Ab response or persistence.
  • ||||||||||  teriflunomide / Generic mfg., fingolimod / Generic mfg.
    Preclinical, Journal:  Immune modulation attenuates infantile neuronal ceroid lipofuscinosis in mice before and after disease onset. (Pubmed Central) -  May 13, 2021   
    Immunodeficient CLN1 mice showed, as previously reported, an improved neurological phenotype in comparison with genuine CLN1 mice which could not be further alleviated by either of the drugs, reflecting a predominantly immune-related therapeutic mechanism of action. The present study supports and strengthens our previous view that repurposing clinically approved immunomodulators may alleviate the course of CLN1 disease in human patients, even though diagnosis usually occurs when symptoms have already emerged.
  • ||||||||||  teriflunomide / Generic mfg.
    Review, Journal:  Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS. (Pubmed Central) -  May 11, 2021   
    Compared with injectable therapies, oral DMTs are often associated with increased treatment adherence and patient satisfaction, due to a less burdensome route of administration and greater tolerability. This review will summarize the available scientific evidence for injectable DMTs and the oral DMT teriflunomide, including considerations for both treatment-naïve patients initiating a DMT and patients switching from an injectable DMT.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono
    Trial completion date, Trial primary completion date:  DELIVER-MS: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (clinicaltrials.gov) -  Apr 22, 2021   
    P4,  N=800, Recruiting, 
    Finally, this research revealed encouraging outcomes and successfully developed intranasal TNLCGHG nanoformulation as a novel tool for safe delivery of TFM in glioma patients. Trial completion date: Sep 2023 --> Sep 2026 | Trial primary completion date: Dec 2022 --> Dec 2025
  • ||||||||||  teriflunomide / Generic mfg.
    Enrollment open, IO biomarker:  Teriflunomide vs. Placebo During Gluten Challenge in Celiac Disease (clinicaltrials.gov) -  Apr 20, 2021   
    P2a,  N=15, Recruiting, 
    Recruiting --> Active, not recruiting | N=193 --> 117 Not yet recruiting --> Recruiting
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Ocrevus (ocrelizumab) / Roche, Biogen
    [VIRTUAL] Socioeconomic Value of Ocrelizumab in the Treatment of Patients with Relapsing Remitting Multiple Sclerosis () -  Apr 12, 2021 - Abstract #ISPOR2021ISPOR_1104;    
    These cost savings are mostly driven by reduction of healthcare resource utilization and community services ($153.6 million, $82.2 million, and $10.9 million), productivity loss ($35.3 million, $24.3 million, and $3.9 million), and informal care ($17.9 million, $12.2 million, and $2.0 million); values compared with teriflunomide, dimethyl fumarate, and cladribine, respectively. CONCLUSIONS Ocrelizumab for RRMS offers substantial socioeconomic benefits compared with relevant first- and second-line DMTs in Canada.
  • ||||||||||  teriflunomide / Generic mfg.
    Preclinical, Journal, IO biomarker:  Neuroprotective action of teriflunomide in a mouse model of transient middle cerebral artery occlusion. (Pubmed Central) -  Apr 10, 2021   
    Finally, teriflunomide significantly upregulated the number of 5-bromo-20-deoxyuridine (BrdU)/ doublecortin(DCX)-positive cells and expression of mammalian achaete-scute homolog 1 (Mash1), DCX and Pbx1 in subventricular zone (SVZ) on day 7 after stroke. Our results indicate that teriflunomide exhibits protective roles in ischemic stroke by inhibiting neuroinflammation, alleviating BBB disruption and enhancing neurogenesis.
  • ||||||||||  teriflunomide / Generic mfg.
    Journal:  Teriflunomide provides protective properties after oxygen-glucose-deprivation in hippocampal and cerebellar slice cultures. (Pubmed Central) -  Apr 7, 2021   
    Our study suggests that teriflunomide, applied as a post-treatment after an oxygen-glucose-deprivation, has a protective effect on hippocampal and cerebellar cells in organotypic slice cultures of rats. All procedures were conducted under established standards of the German federal state of North Rhine Westphalia, in accordance with the European Communities Council Directive 2010/63/EU on the protection of animals used for scientific purposes.
  • ||||||||||  Fumaderm (dimethyl fumarate) / Biogen
    Clinical, Observational data, Journal:  Estimation and Validation of Ratio-based Conditional Average Treatment Effects Using Observational Data. (Pubmed Central) -  Mar 27, 2021   
    We also provide a validation procedure to check the quality of the estimator on an independent sample. We conduct simulations to demonstrate the finite sample performance of the proposed methods, and illustrate their advantages on real data by examining the treatment effect of dimethyl fumarate compared to teriflunomide in multiple sclerosis patients.
  • ||||||||||  teriflunomide / Generic mfg.
    Biomarker, Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Biomarkers and Disease Activity in Patients Treated With Teriflunomide (Aubagio) (clinicaltrials.gov) -  Mar 24, 2021   
    P=N/A,  N=24, Completed, 
    We conduct simulations to demonstrate the finite sample performance of the proposed methods, and illustrate their advantages on real data by examining the treatment effect of dimethyl fumarate compared to teriflunomide in multiple sclerosis patients. Recruiting --> Completed | N=75 --> 24 | Trial completion date: Feb 2019 --> Dec 2020 | Trial primary completion date: Aug 2018 --> Dec 2020
  • ||||||||||  [VIRTUAL] Industry payments in Neurology Subspecialties: 2014 - 2018 () -  Mar 18, 2021 - Abstract #AAN2021AAN_2057;    
    The introduction of newer medications in a subspecialty coincided with higher industry payments. Identification of these trends and potential motives of the industry spending is critical to address any potential physician bias in prescribing medications.
  • ||||||||||  Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
    [VIRTUAL] First-Hand Experience With Ofatumumab at ASCLEPIOS Study Sites In Germany () -  Mar 18, 2021 - Abstract #AAN2021AAN_1573;    
    After gaining experience with ofatumumab within clinical trials, German neurologists consider ofatumumab a very efficient and safe treatment option. They rate the self-administered subcutaneous injection once a month as offering high convenience for patients and as facilitating processes at high-occupancy clinics and office-based practices.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    [VIRTUAL] High and low efficacy therapy in secondary progressive multiple sclerosis () -  Mar 18, 2021 - Abstract #AAN2021AAN_1549;    
    High efficacy DMT is superior to low efficacy therapy in reducing relapse activity in patients with active SPMS, but not those with inactive SPMS. Pre-treatment inflammatory activity, clinical or radiological, is a treatable target in SPMS which may benefit from higher-efficacy anti-inflammatory therapies.
  • ||||||||||  Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
    [VIRTUAL] Ofatumumab as a potential first-line therapy for relapsing multiple sclerosis in Germany () -  Mar 18, 2021 - Abstract #AAN2021AAN_1535;    
    TROPOS provides insights into current MS patient management and reveals unmet needs of MS-treating neurologists in Germany. It shows ofatumumab’s potential as a first-line treatment and emphasizes the importance of innovative MS therapies, especially for treatment-naïve patients.
  • ||||||||||  Ponvory (ponesimod) / J&J
    [VIRTUAL] Fatigue evolution for patients without relapses on the FSIQ-RMS Symptoms Domain () -  Mar 18, 2021 - Abstract #AAN2021AAN_1502;    
    These results are consistent with the full analysis which yielded a mean difference of -3.57 [95% CLs: −5.83, −1.32]; p=0.0019; favoring ponesimod 20mg relative to teriflunomide 14mg. The robustness and consistency of results in the change from baseline for patients without a confirmed relapse during the study relative to the full analysis suggests a potential treatment effect for ponesimod on MS-related fatigue independent of relapse activity.
  • ||||||||||  dimethyl fumarate / Generic mfg.
    [VIRTUAL] Clinical Characteristics and Outcomes of Multiple Sclerosis Patients with COVID-19 in Toronto, Canada () -  Mar 18, 2021 - Abstract #AAN2021AAN_1483;    
    Our findings suggest that the number of PwMS followed in our clinic in Toronto, Canada, with confirmed COVID-19 was low, without strong representation by a particular DMT. Our findings highlight the regional variability of COVID-19 prevalence and the importance of contextualizing risk at a regional level to optimize the management of PwMS.
  • ||||||||||  teriflunomide / Generic mfg.
    Trial completion:  Effects of Teriflunomide (Aubagio) on Cognitive and Vocational Outcomes in Multiple Sclerosis (clinicaltrials.gov) -  Mar 16, 2021   
    P=N/A,  N=60, Completed, 
    Our findings highlight the regional variability of COVID-19 prevalence and the importance of contextualizing risk at a regional level to optimize the management of PwMS. Recruiting --> Completed